Introduction {#sec1}
============

Preeclampsia is an idiopathic multisystem disorder with partial genetic and immunological etiology \[[@B1]\]. Preeclampsia is marked by elevatory maternal blood pressure and proteinuria after 20 weeks of pregnancy \[[@B2]\]. There are major geographical differences concerning early onset preeclampsia and late onset preeclampsia throughout the world \[[@B3]\]. The physiopathology remains poorly understood, although the involvement of metabolic, immune, angiogenic, and genetic factors are suggested \[[@B3]\]. Several studies \[[@B7],[@B8]\] demonstrated an increased apoptosis level of placental villous trophoblasts in pregnancies complicated by preeclampsia. The Fas Ligand (FasL)--FAS (CD95) system is an essential pathway for the initiation of apoptosis in various cells and tissues \[[@B9]\]. Fas and FasL genes, located on chromosomes 10q24.1 and 1q23 respectively, play pivotal roles in the regulation of the apoptotic pathway and immune tolerance in pregnancy and various aspects of mammalian development, especially in immune system homeostasis \[[@B12],[@B13]\]. Therefore, it is reasonable to hypothesize that the Fas and FasL may be candidate genes for preeclampsia susceptibility.

Recently, several studies \[[@B14]\] reported the association between single-nucleotide polymorphisms (SNPs) in Fas, FasL genes and the risk of preeclampsia. However, the results were inconsistent and conflicting. For instance, Raguema et al. \[[@B14]\], Salimi et al. \[[@B16]\], Nasr et al. \[[@B17]\], Ciarmel et al. \[[@B19]\], and Sziller et al. \[[@B20]\] all found that Fas -670 A/G polymorphism increased the risk of preeclampsia, whereas Masoumi et al. \[[@B15]\] and Lasabova et al. \[[@B18]\] reported that Fas -670 A/G polymorphism was not related to preeclampsia susceptibility. Therefore, we conducted this meta-analysis to verify whether Fas and FasL gene polymorphisms were associated with preeclampsia risk.

Materials and methods {#sec2}
=====================

Literature search {#sec2-1}
-----------------

We searched the Cochrane Library, PubMed and Embase databases to identify studies through August 30, 2018. The following key words were used: 'Fas' or 'TNFRSF6/' or 'CD95' or 'APO-1', 'Fas Ligand' or 'FasL' or 'NFSF6' or 'CD95L', 'SNP' or 'polymorphism' and 'preeclampsia' or 'PE'. No restrictions were placed on the search. Additional initially omitted studies (such as reference lists of identified studies) were identified by hand screening.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

The identified studies conformed to the following criteria: (1) studies that evaluated the association between preeclampsia risk and Fas, FasL gene polymorphisms, (2) studies on human beings, (3) studies provided sufficient data to calculate the pooled odds ratios (ORs) and 95% confidence interval (CIs), and *P* value, and (4) case--control studies. Exclusion criteria were as follows: (1) incomplete data; (2) review or case report; (3) duplicate or overlapped publication. All questionable publications were discussed with consensus. Two reviewers independently screened the titles and abstracts.

Data extraction and quality assessment {#sec2-3}
--------------------------------------

Related information was carefully extracted from included studies. The extracted information from all eligible studies including: author name, publication year, nationality, age, sample size, ethnicity, genotype methods, source of controls, and genotype numbers of cases and controls. Two reviewers independently performed the extraction of data and assessed the study quality based on the Newcastle--Ottawa Scale scores (NOS) \[[@B21]\]. Hardy--Weinberg equilibrium (HWE) in controls was tested by Pearson's χ^2^ test (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The NOS criteria were scored according to three aspects: (1) subject selection: 0--4, (2) comparability of subject: 0--2 and (3) exposure: 0--3. The total NOS scores ranged from 0 (lowest) to 9 (highest). All disagreements were discussed and resolved with consensus.

Statistical analysis {#sec2-4}
--------------------

Stata 12.0 software (StataCorp, College Station, TX, U.S.A.) was used to perform all statistical analyses. We assessed the strength of associations between Fas, FasL genes polymorphisms and preeclampsia risk by ORs and 95%CIs. Stratification analyses were carried out by source of controls (SOC) and genotype methods. *P*\<0.05 was considered statistically significant. Pooled ORs were calculated for all five gene models (allele, dominant, recessive, homozygous and heterozygous). If a *Q*-test indicated *I*^2^ \< 50% or *P*\>0.1 indicated heterogeneity across studies, a fixed-effect model was used. Otherwise, the random-effects model was used \[[@B22]\]. We performed sensitivity analyses by leaving out each study in turn to determine the effect on the test of heterogeneity and evaluate the stability of the overall results. Potential publication bias was assessed by both Begger's and Egger's linear regression test \[[@B23]\]; *P*\<0.05 was considered to indicate statistically significant.

Results {#sec3}
=======

Characteristics of the included studies {#sec3-1}
---------------------------------------

We yielded a total of 108 citations after incipient search. Sixteen citations were selected for further full-text review. Nine citations were excluded due to the following reasons: two citations did not provide detailed genotyping data; four studied other diseases, and three was not case--control study. Eventually, we identified seven eligible citations \[[@B14]\] (834 cases and 1072 controls) containing nine studies. Selection for qualified studies was shown in [Figure 1](#F1){ref-type="fig"}. The characteristics of included studies were summarized in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. The NOS of all included studies ranged from 5 to 7 stars, suggesting that these studies were of high quality.

![Selection for eligible papers included in this meta-analysis](bsr-39-bsr20181901-g1){#F1}

###### Characteristics of included studies

  Author         Year   Nationality   Sample size   Age (mean)   Study gene   Study SNPs   Genotype method   NOS         HWE                    
  -------------- ------ ------------- ------------- ------------ ------------ ------------ ----------------- ----------- ---------- --- --- --- ---
  Raguema        2018   Tunisia       300           300          30.5         31.3         Fas               -670 A/G    PCR-RFLP   3   1   2   Y
                                                                                           FasL              124 A/G     PCR-RFLP   3   1   2   Y
  Masoumi        2016   Iran          153           140          28.2         27.1         Fas               -670 A/G    PCR-RFLP   4   1   2   Y
                                                                                                             -1377 G/A   PCR-RFLP   4   1   2   Y
                                                                                           FasL              -844 C/T    PCR-RFLP   3   1   2   N
  Salimi         2014   Iran          127           139          28.0         26.6         Fas               -670 A/G    PCR        3   0   2   Y
                                                                                           FasL              -844 C/T    PCR        3   0   2   N
  Nasr           2014   Egypt         50            50           26.3         28.6         Fas               -670 A/G    PCR-RFLP   3   1   2   Y
                                                                                           FasL              124 A/G     PCR-RFLP   3   1   2   Y
  Lasabova (1)   2014   Slovak        46            45           NA           NA           Fas               -670 A/G    PCR        3   0   2   Y
  Lasabova (2)   2014   Hungaria      70            78           NA           NA           Fas               -670 A/G    PCR        3   0   2   Y
  Ciarmel        2010   Italy         50            142          NA           NA           Fas               -670 A/G    PCR-RFLP   3   0   2   Y
                                                                                                             124 A/G     PCR-RFLP   3   0   2   Y
  Sziller (1)    2009   USA           31            89           NA           30.0         Fas               -670 A/G    PCR        3   0   2   Y
  Sziller (1)    2009   USA           7             89           NA           30.0         Fas               -670 A/G    PCR        3   0   2   Y

I, Selection; II, Comparability; III, Exposure. Newcastle--Ottawa Scale is available from <http://www.ohri.ca/programs/clinical> epidemiology/oxford.asp

Abbreviation: RFLP, restriction fragment length polymorphism.

###### Genotype distributions of Fas, FasL polymorphisms in the included studies

  Author & Year       SOC   Ethnicity    Allele   Case   Control   Association with preeclampsia                         
  ------------------- ----- ------------ -------- ------ --------- ------------------------------- ---- ----- ----- ---- --------------------
  **Fas -670 A/G**                                                                                                       
  Raguema2018         HB    Caucasians   A        G      105       141                             54   151   118   31   Increased risk
  Masoumi2016         HB    Caucasians   A        G      58        64                              31   47    71    22   Not related
  Salimi2014          HB    Caucasians   A        G      27        68                              32   64    59    16   Increased risk
  Nasr2014            HB    Caucasians   A        G      8         30                              12   18    25    7    Increased risk
  Lasabova(1)2014     HB    Caucasians   A        G      11        24                              11   15    20    10   Not related
  Lasabova (1)2014    HB    Caucasians   A        G      14        39                              17   23    36    19   Not related
  Ciarmel2010         PB    Caucasians   A        G      8         29                              13   46    68    28   Increased risk
  Sziller2005         HB    Caucasians   A        G      5         15                              11   33    37    19   Increased risk
  Sziller2005         HB    Caucasians   A        G      2         2                               3    33    37    19   Not related
  **FasL 124A/G**                                                                                                        
  Raguema2018         HB    Caucasians   A        G      99        145                             56   152   117   31   Increased risk
  Nasr2014            HB    Caucasians   A        G      39        7                               4    31    15    4    May decreased risk
  Ciarmel2010         PB    Caucasians   A        G      36        12                              2    95    38    9    Not related
  **FasL -844C/T**                                                                                                       
  Masoumi 2016        HB    Caucasians   C        T      58        64                              31   70    35    35   Not related
  Salimi2014          HB    Caucasians   C        T      22        69                              36   30    83    26   Not related
  **Fas -1377 G/A**                                                                                                      
  Masoumi 2016        HB    Caucasians   G        A      121       28                              4    102   38    0    Increased risk

Abbreviations: HB, hospital-based; NA, not available; PB, population-based.

Meta-analysis of Fas -670 A/G polymorphism {#sec3-2}
------------------------------------------

In the general analysis, we detected a significant association between Fas gene -670 A/G polymorphism with increased risk for preeclampsia (G vs. A: OR, 1.54; 95% CI, 1.35--1.77, *P*\<0.001, [Figure 2](#F2){ref-type="fig"}; AG+GG vs. AA: OR, 1.90; 95% CI, 1.35--2.68, *P*=0.029, [Figure 3](#F3){ref-type="fig"}; GG vs. AA+AG: OR, 1.67; 95% CI, 1.31--2.13, *P*\<0.001; GG vs. AA: OR, 2.31; 95% CI, 1.75--3.06, *P*\<0.001; AG vs. AA: OR, 2.11; 95% CI, 1.34--3.32, *P*=0.001, [Table 3](#T3){ref-type="table"}). Data indicated that GG genotype and G allele were regarded as risk factors for preeclampsia. Stratification analyses were conducted according to SOC and genotype methods. No different results were found ([Table 3](#T3){ref-type="table"}).

![Forest plot shows odds ratio for the association between Fas -670 A/G polymorphism and preeclampsia risk (G vs. A)](bsr-39-bsr20181901-g2){#F2}

![Forest plot shows odds ratio for the association between Fas -670 A/G polymorphism and preeclampsia risk (GG+AG vs. AA)](bsr-39-bsr20181901-g3){#F3}

###### Meta-analysis of the association between Fas, FasL gene polymorphisms and preeclampsia risk

  SNP            Comparison           Category               Category               Studies   OR (95% CI)              *P*-value   *P* for heterogeneity
  -------------- -------------------- ---------------------- ---------------------- --------- ------------------------ ----------- -----------------------
  Fas -670 A/G   G vs. A              Total (fixed model)                           9         **1.54 (1.35, 1.77)**    \<0.001     0.083
                 Allele model         SOC                    HB                     8         **1.54 (1.34, 1.77)**    \<0.001     0.052
                                                             PB                     1         1.58 (0.99, 2.49)        0.051       --
                                      Genotype method        PCR-RFLP               6         **1.50 (1.28, 1.76)**    \<0.001     0.154
                                                             PCR                    3         **1.66 (1.29, 2.13)**    \<0.001     0.066
                 GG+AG                vs. AA                 Total (random model)   9         **1.90 (1.35, 2.68)**    \<0.001     0.029
                 Dominant model       SOC                    HB                     8         **1.85 (1.27, 2.69)**    0.001       0.021
                                                             PB                     1         **2.52 (1.09, 5.79)**    0.030       --
                                      Genotype method        PCR-RFLP               6         **1.80 (1.13, 2.86)**    0.013       0.030
                                                             PCR                    3         **2.25 (1.41, 3.06)**    0.001       0.271
                 GG vs. AG+AA         Total (fixed model)                           9         **1.67 (1.31, 2.13)**    \<0.001     0.673
                 Recessive model      SOC                    HB                     8         **1.70 (1.31, 2.20)**    \<0.001     0.588
                                                             PB                     1         1.43 (0.67, 3.04)        0.353       --
                                      Genotype method        PCR-RFLP               6         **1.72 (1.28, 2.30)**    \<0.001     0.912
                                                             PCR                    3         **1.58 (1.02, 2.43)**    \<0.001     0.126
                 GG vs. AA            Total (fixed model)                           9         **2.31 (1.75, 3.06)**    \<0.001     0.216
                 Homozygote model     SOC                    HB                     8         **2.29 (1.71, 3.06)**    \<0.001     0.154
                                                             PB                     1         2.67 (0.98, 7.24)        0.054       --
                                      Genotype method        PCR-RFLP               6         **2.20 (1.58, 3.08)**    \<0.001     0.335
                                                             PCR                    3         **2.60 (1.56, 4.33)**    \<0.001     0.092
                 AG vs. AA            Total (random model)                          9         **2.11 (1.34, 3.32)**    0.001       0.001
                 Heterozygote model   SOC                    HB                     8         **1.82 (1.19, 2.79)**    0.006       0.010
                                                             PB                     1         **5.75 (2.31, 14.29)**   \<0.001     --
                                      Genotype method        PCR-RFLP               6         **2.53 (1.25, 5.11)**    0.009       \<0.001
                                                             PCR                    3         **1.94 (1.28, 2.93)**    0.002       0.557
  FasL 124A/G    G vs. A              Total (random model)                          3         0.99 (0.47, 2.07)        0.968       0.002
                 Allele model         SOC                    HB                     2         1.08 (0.37, 3.13)        0.890       0.005
                                                             PB                     1         0.78 (0.42, 1.43)        0.413       --
                 GG+AG                vs. AA                 Total (random model)             0.97 (0.38, 2.51)        0.951       0.001
                 Dominant model                              HB                     2         1.04 (0.24, 4.54)        0.961       0.002
                                                             PB                     1         0.79 (0.39, 1.60)        0.506       --
                 GG vs. AG+AA         Total (fixed model)                                     **1.70 (1.11, 2.59)**    0.014       0.277
                 Recessive model                             HB                     2         **1.87 (1.19, 2.92)**    0.006       0.0374
                                                             PB                     1         0.62 (0.13, 2.95)        0.544       --
                 GG vs. AA            Total (random model)                                    1.34 (0.45, 3.98)        0.603       0.069
                 Homozygote model                            HB                     2         1.81 (0.57, 5.78)        0.318       0.114
                                                             PB                     1         0.59 (0.12, 2.85)        0.508       --
                 AG vs. AA            Total (random model)                                    0.92(0.36, 2.35)         0.860       0.003
                 Heterozygote model                          HB                     2         0.90(0.18, 4.46)         0.900       0.003
                                                             PB                     1         0.83(0.39, 1.77)         0.636       --
  FasL -844C/T   T vs. C              Total (fixed model)                                     1.24 (0.98, 1.57)        0.077       0.608
                 Allele model                                                                                                      
                 TT+TC vs. CC         Total (fixed model)                                     **1.51 (1.04, 2.19)**    0.029       0.574
                 Dominant model                                                                                                    
                 TT vs. TC+CC         Total (random model)                                    1.14 (0.51, 2.53)        0.748       0.045
                 Recessive model                                                                                                   
                 TT vs. CC            Total (fixed model)                                     1.33 (0.84, 2.12)        0.222       0.243
                 Homozygote model                                                                                                  
                 TC vs. CC            Total (random model)                                    1.62(0.84, 3.10)         0.148       0.117
                 Heterozygote model                                                                                                

\*Bold values are statistically significant (*P*\<0.05).

We assessed sensitivity analysis by leaving out each study in turn in each genetic model for -670 A/G polymorphism. The pooled ORs for the effects of the SNPs on the risk for preeclampsia risk indicated that our data were credible. Both Egger's and Begg's tests were used to evaluate the publication bias of this meta-analysis. Our data revealed that there was no obvious publication bias for Fas -670 A/G polymorphism (data not shown).

Meta-analysis of FasL gene 124A/G and -844C/T polymorphisms {#sec3-3}
-----------------------------------------------------------

Results of pooled analysis on the association between FasL gene 124A/G polymorphism and preeclampsia risk were shown in [Table 3](#T3){ref-type="table"}. GG genotype (GG vs. AA+AG: OR, 1.70, 95% CI, 1.11--2.59, *P*=0.014) for the 124A/G polymorphism increased the risk of preeclampsia. We also detected a significant association between FasL gene -844C/T polymorphism with increased risk for preeclampsia (TT+TC vs. CC: OR, 1.51, 95% CI, 1.04--2.19, *P*=0.029).

The Fas gene -1377 G/A polymorphism was investigated only in one study \[[@B15]\], which reported a significant association ([Table 2](#T2){ref-type="table"}). Nevertheless, further replication studies are required to confirm the associations.

Discussion {#sec4}
==========

In this meta-analysis, our data showed that the Fas -670 A/G polymorphism, FasL 124A/G polymorphism, and FasL -844C/T polymorphism increased the risk of preeclampsia among Caucasians. Stratification analyses of genotype methods and SOC also yielded similar increased risks for preeclampsia.

Some studies provided evidence that disturbances in apoptosis were associated with increased risk for preeclampsia \[[@B1],[@B19]\]. Fas and FasL pathways are involved in the regulation of immune tolerance in pregnancy, apoptotic pathways, and various aspects of mammalian development \[[@B12],[@B24]\]. Recently, many studies investigated the association between Fas and FasL gene polymorphisms and preeclampsia risk. However, they obtained inconsistent findings. Sziller et al. \[[@B20]\] first reported the Fas A-670G polymorphism in 38 pregnant women with preeclampsia and 89 controls. They showed that Fas A-670G polymorphism was associated with increased risk for preeclampsia in overall analysis \[[@B20]\]. In addition, subgroup analysis also indicated that this SNP was related to risk of preeclampsia-associated intrauterine growth restriction in women who deliver at \<37 weeks \[[@B20]\]. Similar increased risks were replicated in an Italian population study by Ciarmela et al. \[[@B19]\], an Iranian population by Salimi et al. \[[@B16]\], an Egyptian population by Nasr et al. \[[@B17]\], and a Tunisian population by Raguem et al. \[[@B14]\]. It is of note that the finding of Masoumi et al. \[[@B15]\] from southeast Iran was in contrast with the investigation by abovementioned studies. Ethnicity factor cannot explain the contradictory results of Salimi et al. \[[@B16]\] and Masoumi et al. \[[@B15]\], because they were both from the Iranian population. Study with 116 preeclamptic women and 123 healthy control subjects from Lasabova et al. \[[@B18]\] also did not obtain positive findings for Fas A-670G polymorphism. Due to the conflicting results of these studies, it is necessary to conduct a meta-analysis to address these issues. Meta-analysis is utilized to combine the data based on a single study to yield conclusive conclusions. In this meta-analysis, we found that Fas -670 A/G polymorphism increased the risk of preeclampsia among Caucasians. Stratification analyses of genotype methods and SOC also uncovered similar results for preeclampsia. As for the remaining three SNPs, this meta-analysis suggested that the FasL 124A/G and FasL -844C/T polymorphisms also were related to increased risk for preeclampsia. Only one study \[[@B15]\] explored Fas -1377 G/A polymorphism and showed this SNP increased the risk of preeclampsia. To our best knowledge, this study is the first meta-analysis investigating the association between Fas and FasL gene polymorphisms and preeclampsia susceptibility.

Some limitations in this meta-analysis should be considered. First, the heterogeneity of this meta-analysis was somewhat high. Second, we could not conduct some stratification analyses of other potential factors including smoking and drinking. Third, our results were based on unadjusted estimates for confounding factors, which might have affected the final results. Fourth, because of the lack of relevant data, potential gene--gene and gene--environment interactions were not performed. Fifth, the sample sizes of this meta-analysis were not large, which may lead to reduced statistical power. Last but not least, we did not explore the Asian populations due to lack of relevant studies.

In conclusion, this meta-analysis indicates that Fas and FasL gene polymorphisms increase the risk of preeclampsia risk. Further studies with large sample sizes in other populations are urgently needed to confirm the findings of this meta-analysis.
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